在不确定的急性肝衰竭中进行遗传评估:一项后期分析
Chunya Wang1, Meina Li2, Zhenhua Liu3
1Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
概括
不确定的急性肝衰竭 (ALF) 的遗传分析确定了潜在的候选基因,包括ATP7B,UGT1A1,POLG和TTC37. 整体外因子测序有助于理解ALF病因,但基因型-表型相关性仍然存在挑战.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 遗传学 遗传学 是一个
- 医学诊断 医学诊断 医学诊断
背景情况:
- 关于原因不明的急性肝衰竭 (ALF) 的数据有限.
- 研究不确定的ALF的遗传基础对于推进诊断能力至关重要.
研究的目的:
- 使用遗传方法对未确定的ALF病例进行后期分析.
- 为了确定潜在的遗传变异,有助于不确定的ALF的发病.
主要方法:
- 整体外体序列测序 (WES) 在未确定ALF.患者的储存血液样本上进行.
- 分析的重点是识别相关基因内的遗传变异.
主要成果:
- 在成人和儿科患者的一个子集中,在ATP7B,UGT1A1,POLG和TTC37基因中确定了基因变异.
- 具体的异合体和同合体变体被详细介绍为每个已识别的基因.
- 在剩余的患者中没有发现与临床相关的变异.
结论:
- 整个外体序列测序是发现未确定ALF.候选基因的宝贵工具.
- 由于基因型-表型一致性不完整,在实现准确诊断方面仍然存在挑战.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Acute Kidney Injury IV: Diagnostic Studies and Prevention
582
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
582


